Biological and Environmental Research Ontology

Last uploaded: December 23, 2022

Id	http://purl.obolibrary.org/obo/NCIT_C106235 http://purl.obolibrary.org/obo/NCIT_C106235
Preferred Name	Brilanestrant
Definitions	An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.
Type	http://www.w3.org/2002/07/owl#Class

definition	An orally available, nonsteroidal selective estrogen receptor degrader (SERD), with potential antineoplastic activity. Upon oral administration, brilanestrant binds to the estrogen receptor and induces a conformational change that results in the degradation of the receptor. This may inhibit the growth and survival of ER-expressing cancer cells.
prefLabel	Brilanestrant
label	Brilanestrant
PDQ_Closed_Trial_Search_ID	748900
code	C106235
Has_Target	http://purl.obolibrary.org/obo/NCIT_C38361
prefixIRI	NCIT:C106235
in_subset	http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C157711 http://purl.obolibrary.org/obo/NCIT_C157712 See more See less
Display_Name	Brilanestrant
Preferred_Name	Brilanestrant
FDA_UNII_Code	9MM2R1A06R
Contributing_Source	CTRP FDA
Maps_To	Brilanestrant
CAS_Registry	1365888-06-7
NCI_Drug_Dictionary_ID	748900
type	http://www.w3.org/2002/07/owl#Class
Is_Value_For_GDC_Property	http://purl.obolibrary.org/obo/NCIT_C1909
subClassOf	http://purl.obolibrary.org/obo/NCIT_C2116
PDQ_Open_Trial_Search_ID	748900
Semantic_Type	Organic Chemical Pharmacologic Substance
UMLS_CUI	C3827161

Delete	Subject	Author	Type	Created
No notes to display